Prostate Cancer Trial, Recruiting NCT05000827 Sponsor: Canisius-Wilhelmina Hospital Condition: Prostate Cancer
Back to Prostate Cancer

Prostate Cancer Trial, Recruiting

NCT05000827
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been diagnosed with prostate cancer confirmed by a biopsy showing a specific type called adenocarcinoma
  • People for whom doctors have determined that an extended removal of lymph nodes in the pelvis, combined with robotic surgery to remove the prostate, is the recommended treatment (based on specific risk calculation tools used by the medical team)
  • People who are considered medically suitable to undergo robotic prostate removal surgery with extended pelvic lymph node removal
  • People who are mentally able to understand the potential benefits and demands of taking part in the study
  • People who are willing and able to provide written consent to participate
  • People with no known allergies to the PSMA tracer (a substance used in a special type of scan)

Who may not be able to join:

  • People who have previously been diagnosed with or treated for prostate cancer
  • People who have another cancer diagnosis at the same time (except a common, low-risk type of skin cancer called Basal Cell Carcinoma)
  • People who are unwilling or unable to undergo the required PSMA PET/CT scan and/or the planned surgical procedures
  • People whose prostate cancer does not show up on a PSMA scan in the area of the main tumour (confirm with trial site)
  • People whose cancer has already spread to distant parts of the body

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 6 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Jean-Paul A. van Basten, Canisius-Wilhelmina Hospital

Phone: 0681806668

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Canisius-Wilhelmina Hospital
Registry
ClinicalTrials.gov
Start date
28 July 2021
Est. completion
31 July 2025

Where this trial is recruiting

🇳🇱 Netherlands

Primary endpoints

Difference in biochemical recurrence rate between groups.

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 6 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov